Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect
News and Views Disease Lists/Categories
About
About MalaCards Datasets Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
ALL
MCID: LKM062
MIFTS: 69

Leukemia, Acute Lymphoblastic (ALL)

Categories: Blood diseases, Cancer diseases, Genetic diseases, Immune diseases, Rare diseases
Genes Variations Tissues Related diseases Publications Pathways Symptoms & Phenotypes Drugs
Sources

Aliases & Classifications for Leukemia, Acute Lymphoblastic

About this section

MalaCards integrated aliases for Leukemia, Acute Lymphoblastic:

Name: Leukemia, Acute Lymphoblastic 57 73 37
Acute Lymphoblastic Leukemia 12 74 20 58 6 15 17
Acute Lymphocytic Leukemia 74 20 58 42 71
All 57 12 20 58 73
B-Cell Acute Lymphoblastic Leukemia 36 29 17
Leukemia, Acute Lymphocytic, Susceptibility to, 1 57 13
Leukemia, Acute Lymphoblastic, Susceptibility to 29 6
Precursor Lymphoblastic Lymphoma/leukemia 12 17
Acute Lymphoblastic Leukaemia 12 15
Leukemia, Acute Lymphoblastic, Susceptibility to, 3 71
Precursor Cell Lymphoblastic Leukemia-Lymphoma 44
Precursor Cell Lymphoblastic Leukemia Lymphoma 71
Leukemia Acute Lymphoblastic B-Hyperdiploid 73
Childhood Acute Lymphoblastic Leukemia 73
Acute Lymphoblastic Leukemia/lymphoma 58
Leukemia B-Cell Acute Lymphoblastic 73
Leukemia T-Cell Acute Lymphoblastic 73
Leukemia, Acute Lymphoblastic, 3 73
Leukemia, Lymphocytic, Acute, L1 71
Leukemia Acute Lymphoblastic 1 73
Leukemia, Acute, Lymphoblastic 39
Leukemia, Acute Lymphocytic 1 57
Leukemia Acute Lymphocytic 1 73
Lymphoblastic Leukemia Acute 54
Acute Lymphocytic Leukaemia 12
Precursor Lymphoid Neoplasm 58
Leukemia Acute Lymphocytic 73
All3 73
All1 73

Characteristics:

Orphanet epidemiological data:

58
acute lymphoblastic leukemia
Prevalence: 1-9/100000 (France),1-9/100000 (United States),1-5/10000 (United States),1-5/10000 (Europe); Age of onset: All ages; Age of death: any age;

HPO:

31
leukemia, acute lymphoblastic:
Inheritance somatic mutation polygenic inheritance


Classifications:

MalaCards categories:
Global: Rare diseases Cancer diseases Genetic diseases
Anatomical: Blood diseases Immune diseases
See all MalaCards categories (disease lists)
ICD10: 32 33
Orphanet: 58  
Rare haematological diseases


External Ids:

Disease Ontology 12 DOID:9952
OMIM® 57 613065
KEGG 36 H00001
ICD9CM 34 204.0
MeSH 44 D054198
NCIt 50 C3167 C7055
SNOMED-CT 67 128822004
ICD10 32 C91.0 C91.00
ICD10 via Orphanet 33 C91.0
UMLS via Orphanet 72 C0023449
Orphanet 58 ORPHA513
SNOMED-CT via HPO 68 124975008 91857003
UMLS 71 C0023449 C0023452 C1335469 more
Sources

Summaries for Leukemia, Acute Lymphoblastic

About this section
GARD : 20 Acute lymphoblastic leukemia (ALL) is a type of cancer in which the bone marrow makes too many lymphocytes (a type of white blood cell). It may develop in children or adults. ALL spreads to the blood fairly quickly, and then may spread to other areas of the body such as the lymph nodes, liver, spleen, central nervous system, and testicles (in males). Signs and symptoms of ALL may include fever, easy bruising or bleeding, feeling tired, loss of appetite, pain in the bones or abdomen, and painless lumps in the neck, underarm, stomach, or groin. ALL is typically caused by random, non-inherited changes in the DNA of immature lymphocytes called lymphoblasts. However, some people may inherit a genetic susceptibility to developing ALL. The risk to develop ALL may also be increased by past treatment for cancer, and by having certain genetic conditions or syndromes. Having one or more risk factors does not mean that a person definitely will develop ALL. Treatment of ALL depends on the person's age, how advanced the cancer is, and whether certain genetic changes are found in cancer cells. Treatment options may involve systemic and/or intrathecal chemotherapy, radiation therapy, targeted therapy, and/or a stem cell transplant. Biologic therapy and chimeric antigen receptor (CAR) T-cell therapy are currently being studied as treatment options and may be used when other therapies are not working. The chance of recovery also depends on many factors. With treatment, about 98% of children with ALL go into remission, and 85% of those with first-time ALL are expected have no long-term complications. The chance of recovery for adults is not as high, as 20-40% of adults are cured with current treatments.

MalaCards based summary : Leukemia, Acute Lymphoblastic, also known as acute lymphoblastic leukemia, is related to childhood acute lymphocytic leukemia and leukemia, acute lymphoblastic 3, and has symptoms including angina pectoris, chest pain and bone pain. An important gene associated with Leukemia, Acute Lymphoblastic is PAX5 (Paired Box 5), and among its related pathways/superpathways are Transcriptional misregulation in cancer and MicroRNAs in cancer. The drugs Epirubicin and Morphine have been mentioned in the context of this disorder. Affiliated tissues include Blood, and related phenotypes are acute lymphoblastic leukemia and neoplasm

Disease Ontology : 12 A acute leukemia that is characterized by over production of lymphoblasts.

OMIM® : 57 Acute lymphoblastic leukemia (ALL), also known as acute lymphocytic leukemia, is a subtype of acute leukemia, a cancer of the white blood cells. Somatically acquired mutations in several genes have been identified in ALL lymphoblasts, cells in the early stages of differentiation. Germline variation in certain genes may also predispose to susceptibility to ALL (Trevino et al., 2009). (613065) (Updated 05-Mar-2021)

MedlinePlus : 42 Leukemia is cancer of the white blood cells. White blood cells help your body fight infection. Your blood cells form in your bone marrow. In leukemia, however, the bone marrow produces abnormal white blood cells. These cells crowd out the healthy blood cells, making it hard for blood to do its work. In acute lymphocytic leukemia (ALL), also called acute lymphoblastic leukemia, there are too many of specific types of white blood cells called lymphocytes or lymphoblasts. ALL is the most common type of cancer in children. Possible risk factors for ALL include being male, being white, previous chemotherapy treatment, exposure to radiation, and for adults, being older than 70. Symptoms of ALL include: Weakness or feeling tired Fever Easy bruising or bleeding Bleeding under the skin Shortness of breath Weight loss or loss of appetite Pain in the bones or stomach Pain or a feeling of fullness below the ribs Painless lumps in the neck, underarm, stomach, or groin Tests that examine the blood and bone marrow diagnose ALL. Treatments include chemotherapy, radiation therapy, stem cell transplants, and targeted therapy. Targeted therapy uses drugs or other substances that attack specific cancer cells with less harm to normal cells. Once the leukemia is in remission, you need additional treatment to make sure that it does not come back. NIH: National Cancer Institute

KEGG : 36 Acute lymphocytic leukemia (ALL) is a clonal stem cell malignancy of excessive lymphoblast proliferation. It is now understood that ALL and lymphoblastic lymphoma are the same disease entities at the morphologic and immunophenotypic levels and classified as either B- and T-cell lymphoblastic leukemia/lymphoma (B-ALL and T-ALL). In the case of B-ALL, numerous reports have demonstrated that recurring genetic abnormalities are associated with sufficiently unique clinical, immunophenotypic, and/or prognostic features so that they can be considered as distinct entities. The most common rearrangements observed in B-ALL are the t(12;21) (p13;q22) rearrangement resulting in expression of the ETV6-RUNX1 fusion (TEL-AML1); the t(1;19) (q23;p13) translocation that results in expression of the TCF3 (E2A) fusion partner, (also known as TCF3) TFPT-PBX1 fusion (E2A-PBX); the t(9;22) (q34;q11.2) "Philadelphia" chromosome resulting in expression of the BCR-ABL1 fusion; and rearrangements of MLL (also known as KMT2A) at 11q23 to a diverse array of fusion partners. If none of these specific genetic abnormalities are found, the designation of "B lymphoblastic leukemia/lymphoma, not otherwise specified," is appropriate.

UniProtKB/Swiss-Prot : 73 Leukemia, acute lymphoblastic: A subtype of acute leukemia, a cancer of the white blood cells. ALL is a malignant disease of bone marrow and the most common malignancy diagnosed in children. The malignant cells are lymphoid precursor cells (lymphoblasts) that are arrested in an early stage of development. The lymphoblasts replace the normal marrow elements, resulting in a marked decrease in the production of normal blood cells. Consequently, anemia, thrombocytopenia, and neutropenia occur to varying degrees. The lymphoblasts also proliferate in organs other than the marrow, particularly the liver, spleen, and lymphnodes.
Leukemia, acute lymphoblastic, 3: A subtype of acute leukemia, a cancer of the white blood cells. Acute lymphoblastic anemia is a malignant disease of bone marrow and the most common malignancy diagnosed in children. The malignant cells are lymphoid precursor cells (lymphoblasts) that are arrested in an early stage of development. The lymphoblasts replace the normal marrow elements, resulting in a marked decrease in the production of normal blood cells. Consequently, anemia, thrombocytopenia, and neutropenia occur to varying degrees. The lymphoblasts also proliferate in organs other than the marrow, particularly the liver, spleen, and lymphnodes.

Wikipedia : 74 Acute lymphoblastic leukemia (ALL) is a cancer of the lymphoid line of blood cells characterized by the... more...

Sources

Related Diseases for Leukemia, Acute Lymphoblastic

About this section

Diseases in the Leukemia, Acute Lymphoblastic family:

Leukemia, Acute Lymphoblastic 2 Leukemia, Acute Lymphoblastic 3

Diseases related to Leukemia, Acute Lymphoblastic via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 1311)
# Related Disease Score Top Affiliating Genes
1 childhood acute lymphocytic leukemia 34.3 PAX5 NBN GNB1 FLT3 ETV6 ACTB
2 leukemia, acute lymphoblastic 3 33.5 PAX5 FLT3 ETV6
3 childhood b-cell acute lymphoblastic leukemia 33.1 PAX5 CRLF2
4 b-lymphoblastic leukemia/lymphoma 32.6 PAX5 FLT3 ETV6
5 lymphoblastic leukemia, acute, with lymphomatous features 32.6 JAK2 CRLF2
6 down syndrome 32.0 MIR155 JAK2 FLT3 ETV6 CRLF2
7 myeloproliferative neoplasm 31.9 MIR155 JAK2 FLT3 ETV6
8 thrombocytopenia 31.9 PAX5 MIR155 JAK2 FLT3 ETV6
9 myelofibrosis 31.9 JAK2 FLT3 ETV6 CDKN2B-AS1
10 adult acute lymphocytic leukemia 31.8 PAX5 ETV6 CRLF2
11 lymphoma, non-hodgkin, familial 31.8 PAX5 NBN MIR155 JAK2 FLT3 ETV6
12 leukemia, chronic lymphocytic 31.6 PAX5 MIR155 JAK2 GNB1 FLT3
13 myeloma, multiple 31.6 MIR335 JAK2 FLT3 ACTB
14 leukemia 31.6 PAX5 JAK2 FLT3 ETV6 CRLF2 CDKN2B-AS1
15 b-lymphoblastic leukemia/lymphoma with iamp21 31.4 PAX5 ETV6 CRLF2
16 etv6 thrombocytopenia and predisposition to leukemia 31.4 JAK2 FLT3 ETV6
17 hematologic cancer 31.4 XIST PAX5 MIR335 MIR196B MIR155 JAK2
18 lymphoma, hodgkin, classic 31.4 PAX5 MIR155 JAK2
19 leukemia, acute monocytic 31.4 MIR155 FLT3 ACTB
20 retinitis pigmentosa 11 31.3 XIST MIR335 ETV6 ACTB
21 leukemia, acute myeloid 31.2 PAX5 MIR335 MIR155 JAK2 FLT3 ETV6
22 atypical chronic myeloid leukemia 31.1 JAK2 FLT3 ETV6
23 acute myeloid leukemia with abnormal bone marrow eosinophils inv(16)(p13q22) or t(16;16)(p13;q22) 30.9 FLT3 ETV6
24 myelodysplastic/myeloproliferative neoplasm 30.9 JAK2 FLT3 ETV6
25 acute leukemia 30.9 PAX5 JAK2 FLT3 ETV6
26 chronic eosinophilic leukemia 30.9 JAK2 FLT3 ETV6
27 leukemia, acute lymphoblastic 2 11.6
28 childhood t-cell acute lymphoblastic leukemia 11.6
29 b-cell adult acute lymphocytic leukemia 11.6
30 null-cell leukemia 11.4
31 acute lymphoblastic leukemia congenital sporadic aniridia 11.3
32 medulloblastoma 11.2
33 b-lymphoblastic leukemia/lymphoma with tcf3-pbx1 11.2
34 t-cell adult acute lymphocytic leukemia 11.2
35 t-cell acute lymphoblastic leukemia 11.2
36 pdgfra-associated chronic eosinophilic leukemia 11.2
37 childhood leukemia 11.0
38 neutropenia 10.8
39 mental retardation, autosomal dominant 33 10.8 PAX5 JAK2 ETV6 CRLF2
40 hypereosinophilic syndrome 10.8
41 aspergillosis 10.7
42 cebpa-associated familial acute myeloid leukemia 10.7 JAK2 FLT3 ETV6
43 hepatic veno-occlusive disease 10.7
44 osteonecrosis 10.7
45 chromosomal triplication 10.6
46 leiomyoma, uterine 10.6 MIR335 MIR203A MIR196B
47 splenomegaly 10.6
48 chromosomal duplication syndrome 10.6 MIR155 ETV6 CRLF2
49 interleukin-7 receptor alpha deficiency 10.6
50 48,xyyy 10.6

Graphical network of the top 20 diseases related to Leukemia, Acute Lymphoblastic:



Diseases related to Leukemia, Acute Lymphoblastic
Sources

Symptoms & Phenotypes for Leukemia, Acute Lymphoblastic

About this section

Human phenotypes related to Leukemia, Acute Lymphoblastic:

31
# Description HPO Frequency HPO Source Accession
1 acute lymphoblastic leukemia 31 HP:0006721

Clinical features from OMIM®:

613065 (Updated 05-Mar-2021)

UMLS symptoms related to Leukemia, Acute Lymphoblastic:


angina pectoris, chest pain, bone pain, edema

MGI Mouse Phenotypes related to Leukemia, Acute Lymphoblastic:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 neoplasm MP:0002006 9.1 ACTB ETV6 FLT3 JAK2 NBN PAX5
Sources

Drugs & Therapeutics for Leukemia, Acute Lymphoblastic

About this section

Drugs for Leukemia, Acute Lymphoblastic (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 477)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Epirubicin Approved Phase 4 56420-45-2 41867
2
Morphine Approved, Investigational Phase 4 57-27-2 5288826
3
Nicotine Approved Phase 4 54-11-5 942 89594
4
Teniposide Approved Phase 4 29767-20-2 34698
5
Micafungin Approved, Investigational Phase 4 235114-32-6 3081921 477468
6
Posaconazole Approved, Investigational, Vet_approved Phase 4 171228-49-2 147912
7
Oprelvekin Approved, Investigational Phase 4 145941-26-0
8
Vitamin D Approved, Nutraceutical, Vet_approved Phase 4 1406-16-2
9
Vitamin D3 Approved, Nutraceutical Phase 4 67-97-0 6221 5280795
10
Ergocalciferol Approved, Nutraceutical Phase 4 50-14-6 5280793
11
Calcifediol Approved, Nutraceutical Phase 4 19356-17-3 6433735 5283731
12
Ethylene Phase 4 74-85-1 6325
13 Calcium, Dietary Phase 4
14 Calciferol Phase 4
15 Heptavalent Pneumococcal Conjugate Vaccine Phase 4
16 Vitamin D2 Phase 4
17 Ergocalciferols Phase 4
18 Hydroxycholecalciferols Phase 4
19 Neurotransmitter Agents Phase 4
20 Adrenergic Agents Phase 4
21 Atomoxetine Hydrochloride Phase 4
22
Calcium Nutraceutical Phase 4 7440-70-2 271
23
Pentoxifylline Approved, Investigational Phase 2, Phase 3 6493-05-6 4740
24
Lorazepam Approved Phase 3 846-49-1 3958
25
Erythromycin Approved, Investigational, Vet_approved Phase 2, Phase 3 114-07-8 12560
26
Dactinomycin Approved, Investigational Phase 3 50-76-0 2019 457193
27
Cobalt Approved, Experimental Phase 3 7440-48-4 104729
28
Calcium carbonate Approved, Investigational Phase 3 471-34-1
29
Methylcobalamin Approved, Investigational Phase 2, Phase 3 13422-55-4
30
Hydroxocobalamin Approved Phase 2, Phase 3 13422-51-0 11953898 15589840
31
Ofloxacin Approved Phase 3 82419-36-1 4583
32
Levofloxacin Approved, Investigational Phase 3 100986-85-4 149096
33
Chlorhexidine Approved, Vet_approved Phase 3 55-56-1 9552079 2713
34
Carvedilol Approved, Investigational Phase 3 72956-09-3 2585
35
Enalaprilat Approved Phase 3 76420-72-9 6917719
36
Enalapril Approved, Vet_approved Phase 3 75847-73-3 5362032 40466924
37
Etidronic acid Approved Phase 3 2809-21-4, 7414-83-7 3305
38
Risedronate Approved, Investigational Phase 3 105462-24-6 5245
39
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 3 1177-87-3
40
Dexamethasone Approved, Investigational, Vet_approved Phase 3 50-02-2 5743
41
Daunorubicin Approved Phase 3 20830-81-3 30323
42 Prednisolone acetate Approved, Vet_approved Phase 3 52-21-1
43
Prednisolone Approved, Vet_approved Phase 3 50-24-8 5755
44
Methylprednisolone hemisuccinate Approved Phase 3 2921-57-5
45
Methylprednisolone Approved, Vet_approved Phase 3 83-43-2 6741
46
Prednisolone phosphate Approved, Vet_approved Phase 3 302-25-0
47
Vindesine Approved, Investigational Phase 3 53643-48-4, 59917-39-4 40839
48
Ifosfamide Approved Phase 3 3778-73-2 3690
49
Idarubicin Approved Phase 2, Phase 3 58957-92-9 42890
50
Decitabine Approved, Investigational Phase 3 2353-33-5 451668

Interventional clinical trials:

(show top 50) (show all 1575)
# Name Status NCT ID Phase Drugs
1 Philadelphia -Negative High-risk Children Acute Lymphoblastic Leukemia(ALL) Treatment:Induction Therapy:Vincristine(V),Idarubicin(I),L-asparaginase(L),Dexamethasone(D);Consolidation:V+Daunorubicin(D)+L+D, Methotrexate,Cytarabine Unknown status NCT01990807 Phase 4 Idarubicin(IDA)
2 PEG-asparaginase During Two Treatment Courses in the Treatment of Childhood Acute Lymphoblastic Leukemia Unknown status NCT00192673 Phase 4 PEG-asparaginase
3 Plasma Kinetics of Tablet and Liquid Formulations of 6-mercaptopurine in Childhood Acute Lymphoblastic Leukemia. Unknown status NCT01906671 Phase 4 Xaluprine;Puri-Nethol
4 Clinical Study of GD-2008 ALL Protocol for Childhood Acute Lymphoblastic Leukemia in Guangdong Province Unknown status NCT00846703 Phase 4 6-mercaptopurine, Methotrexate;6-mercaptopurine, Methotrexate, Vincristine, Dexamethasone
5 Medical Research Council Working Party on Leukaemia in Children UK National Acute Lymphoblastic Leukaemia (ALL) Trial: UKALL 2003 Unknown status NCT00222612 Phase 4 Standard childhood UK ALL protocol;Intensified treatment including Capizzi maintenance
6 German Multicenter Study for Treatment Optimisation in Acute Lymphoblastic Leukemia in Adults and Adolescents Above 15 Years (Amend 3) (GMALL 07/2003) Unknown status NCT00198991 Phase 4 Cyclophosphamide;Dexamethasone;Vincristine;daunorubicin;Asparaginase;Methotrexate;Cytarabine;Mercaptopurine;G-CSF;Vindesine;VP16;Prednisolone;Adriamycin;Thioguanine;VM26;Idarubicin;Fludarabine;Cladribine
7 Multicenter Study To Optimize Treatment in Elderly Patients (> 55 Years, No Upper Age Limit) With Acute Lymphoblastic Leukemia (GMALL Elderly 1/2003)(Amend 2) Unknown status NCT00198978 Phase 4 Cyclophosphamide;Dexamethasone / Prednisolone;Cytarabine;Idarubicin;Granulocyte-Colony-Stimulating Factor;Mercaptopurine;Methotrexate;Rituximab;HDARAC;Vincristine;Depocyte;Asparaginase
8 The Combination of Lower Dosage of Chemotherapy With Tyrosine Kinase Inhibitor to Treat Newly Diagnosed ph+ Acute Lymphoblastic Leukemia Patients Unknown status NCT02690922 Phase 4 Dasatinib;prednisone;dexamethasone;methotrexate
9 An Open-label,Multi-center,Prospective Study of Idarubicin and Etoposide Intensified Conditioning Regimen Allogeneic Hematopoietic Stem Cell Transplantation for Adult Acute Lymphoblastic Leukemia Unknown status NCT01873807 Phase 4 IDA;CTX;VP-16
10 Intensification Therapy of Mature B-ALL, Burkitt and Burkitt Like and Other High Grade Non-Hodgkin's Lymphoma in Adults Unknown status NCT00797810 Phase 4 Rituximab
11 Ma-Spore ALL 2010 Study Unknown status NCT02894645 Phase 4 Prednisolone;Dexamethasone;L-Asparaginase;Vincristine;Methotrexate;Daunorubicin;Doxorubicin;Cyclophosphamide;Cytarabine;6-Mercaptopurine;Thioguanine;Fludarabine;Imatinib
12 A Clinical Trial of Decitabine Combined With CODOX-M/IVAC in Relapsed or Refractory T-lymphoblastic Lymphoma Unknown status NCT03558412 Phase 4 Decitabine
13 G-CSF Alone or Combination With GM-CSF on Prevention and Treatment of Infection in Children With Malignant Tumor: a Prospective, Multicentre, Randomised Controlled Trial Unknown status NCT02933333 Phase 4
14 ALL-REZ BFM 2002: Protocol for the Treatment of Children With Relapsed Acute Lymphoblastic Leukemia Completed NCT00114348 Phase 4
15 Multicenter Trial for Treatment of Acute Lymphoblastic Leukemia in Adults (05/93) Completed NCT00199069 Phase 4 Asparaginase;Vincristine;Daunorubicin, Adriamycin;Cyclophosphamide;Ifosfamide;Cytarabine;Mitoxantrone;Methotrexate;6-Mercaptopurine;6-Thioguanine;VM26;Dexamethasone / Prednisolone
16 German Multicenter Trial for Treatment Optimisation in Acute Lymphoblastic Leukemia in Adults and Adolescents Above 15 Years With Rituximab for Improvement of Prognosis in CD20 Positive Standard Risk ALL (Amend 2) Completed NCT00199004 Phase 4 Cyclophosphamide;Dexamethasone / Prednisolone;Vincristine;Daunorubicin;Asparaginase;Methotrexate;Cytarabine;Mercaptopurine;G-CSF;Vindesine;VP16;Adriamycin;Thioguanine;VM26;Rituximab
17 Pilot Study for Treatment of Elderly Patients (>65 Years) With Acute Lymphoblastic Leukemia Completed NCT00199095 Phase 4 Adriamycin;Cyclophosphamide;Cytarabine;Dexamethasone;Idarubicin;Ifosfamide;Methotrexate;Mercaptopurine;VM26;Vincristine
18 A Randomized Open-Label Trial of Posaconazole Versus Micafungin for Prophylaxis Against Invasive Fungal Infections During Neutropenia in Patients Undergoing Chemotherapy for Acute Myelogenous Leukemia, Acute Lymphocytic Leukemia or Myelodysplastic Syndrome Completed NCT01200355 Phase 4 micafungin;posaconazole
19 Learning Impairments Among Survivors of Childhood Cancer Completed NCT00576472 Phase 4 Methylphenidate
20 Prospective Study of Rituximab Combined With Chemotherapy for CD20+ Adult Acute Lymphoblastic Leukemia Completed NCT01358253 Phase 4 Cyclophosphamide;Doxorubicin;Vincristine;Dexamethasone;Cytarabine;Methotrexate;Rituximab;6-Mercaptopurine;Prednisone;L-asparaginase
21 Pulses of Vincristine and Dexamethasone During Maintenance in BFM Protocols for Children With Intermediate-Risk Acute Lymphoblastic Leukemia Completed NCT00411541 Phase 4 vincristine;dexamethasone
22 LAL-AR-N-2005: Study Treatment for Children High Risk Acute Lymphoblastic Leukemia Completed NCT00526409 Phase 4 Prednisolone;Daunorubicin;Vincristine;L-Asparaginase;Cyclophosphamide;Methotrexate;Cytosine Arabinoside
23 LAL-Ph-2000: Treatment of Acute Lymphoblastic Leukemia Chromosome Philadelphia Positive Completed NCT00526305 Phase 4 Vincristine;Daunorubicin;Prednisone;L-Asparaginase;Mitoxantrone;Cytosine Arabinoside;Hydrocortisone;Mercaptopurine;Cyclophosphamide;Dexamethasone
24 LAL-BR/2001: Study Treatment to Low Risk ALL Completed NCT00526175 Phase 4 Prednisone;Vincristine;Daunorubicin;L-Asparaginase;Cyclophosphamide;Methotrexate;Cytosine Arabinoside;Mercaptopurine;VP-16
25 Treatment of High Risk Adult Acute Lymphoblastic Leukemia Completed NCT00853008 Phase 4 Vincristine;Daunorubicin;Prednisone;Mitoxantrone;Cytosine Arabinoside;Dexamethasone;Methotrexate (MTX);Cytarabine;ASP;Mercaptopurine;Teniposide;Hydrocortisone
26 PETHEMA LAL-RI/96: Treatment for Patients With Standard Risk Acute Lymphoblastic Leukemia Completed NCT00494897 Phase 4 Asparaginase;Cyclophosphamide;Cytarabine;Daunorubicin;Mercaptopurine;Prednisone;Vincristine;Methotrexate
27 Vaccinating Children After Chemotherapy for Acute Lymphoblastic Leukemia: A Canadian Immunization Research Network Study Completed NCT02447718 Phase 4
28 Multicenter Trial for Treatment of Acute Lymphocytic Leukemia in Adults (Pilot Study 06/99) Completed NCT00199056 Phase 4 Dexamethasone / Prednisolone;Cyclophosphamide;Methotrexate;Vincristine / Vindesine;Daunorubicin;Asparaginase;G-CSF;Cytarabine;6-Mercaptopurine;VP16;Adriamycin;Thioguanine;VM26;Idarubicin;Fludarabine;Ifosfamide
29 Multicenter Trial for Treatment Optimization in T-lymphoblastic Lymphoma in Adults and Adolescents Older Than 15 Years (GMALL T-LBL 1/2004) (Amend 1) Completed NCT00199017 Phase 4 Dexamethasone/Prednisolone;Cyclophosphamide;Vincristine;Daunorubicin;Asparaginase;G-CSF;Mercaptopurine;Cytarabine;Methotrexate;VP16;Vindesine;Adriamycin;Thioguanine;HDARAC;Cladribine
30 Multicenter Study to Optimise Therapy of B-ALL, Burkitt's NHL and High-Grade Non-Hodgkin's Lymphoma in Adults (Amend 7) Completed NCT00199082 Phase 4 Adriamycin;Cyclophosphamide;Cytarabine;Dexamethasone/Prednisolone;VP16;Ifosfamide;Methotrexate;G-CSF;Rituximab;Vincristine/Vindesine
31 The Study on the Pharmacokinetics of Pegylated Recombinant Human Granulocyte Stimulating Factor（PEG-rhG-CSF） in Children and Adolescents Completed NCT02953730 Phase 4 PEG-rhG-CSF
32 A Randomized Phase IV Control Trial of Single High Dose Oral Vitamin D3 (Stoss Therapy) in Pediatric Patients Undergoing HSCT to Prevent Vitamin D Deficiency and Insufficiency During Transplant Completed NCT03176849 Phase 4
33 Effect of Treatment Using rhIL-11 in Patients With Thrombocytopenia After Chemotherapy for Childhood Acute Lymphoblastic Leukemia Completed NCT02314273 Phase 4 rhIL-11
34 A PHASE 4, OPEN-LABEL, RANDOMIZED STUDY OF TWO INOTUZUMAB OZOGAMICIN DOSE LEVELS IN ADULT PATIENTS WITH RELAPSED OR REFRACTORY B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA ELIGIBLE FOR HEMATOPOIETIC STEM CELL TRANSPLANTATION AND WHO HAVE RISK FACTOR(S) FOR VENO-OCCLUSIVE DISEASE Recruiting NCT03677596 Phase 4 inotuzumab ozogamicin-dose level 2;Inotuzumab ozogamicin-dose level 1
35 PROTOCOL FOR THE TREATMENT Acute Lymphoblastic Leukemia With Ph 'NEGATIVE IN ELDERLY PATIENTS (> 55 Years) Recruiting NCT01366898 Phase 4 Dexamethasona, Idarubicine, ARA-C, Methotrexate
36 Treatment Protocol For All Fragile Patients Ph' Negative Over 55 Years Recruiting NCT01358201 Phase 4 vINCRISTINE;Dexamethasone;Methotrexate;Cytosine arabinoside
37 Allogeneic Stem Cell Transplant for Children and Adolescents With Acute Lymoblastic Leukemia FORUM - Pharmacogenomic Study (add-on Study) Recruiting NCT02670564 Phase 4
38 Identification of New Immune Factors Specific of Relapse in Childhood B Lineage Acute Lymphoblastic Leukemia Recruiting NCT02618109 Phase 4
39 Chemotherapy and Imatinib in Young Adults With Acute Lymphoblastic Leukemia Ph (BCR-ABL) POSITIVE Recruiting NCT01491763 Phase 4 Imatinib
40 Hematology , Shanghai Jiaotong University Affiliated Shanghai First People's Hospital, Shanghai, China Recruiting NCT02938741 Phase 4 Anti-human Thymoglobulin;Placebo
41 Determinants of Mercaptopurine Toxicity in Paediatric Acute Lymphoblastic Enrolling by invitation NCT03920813 Phase 4 Mercaptopurine
42 A Phase 4, Multi-center Open-label Feasibility Study to Evaluate Outpatient Blinatumomab Administration in Adult Subjects With Minimal Residual Disease (MRD) of B-precursor Acute Lymphoblastic Leukemia (ALL) in Complete Hematologic Remission Not yet recruiting NCT04506086 Phase 4 Blinatumomab
43 ProphyALL - Pilot Study on Safety of Four Weekly Administrations of 7 mg/kg of Liposomal Amphotericin B (AmBisome®) in Antifungal Primary Prophylaxis Treatment of Elderly Patients With Acute Lymphoblastic Leukemia Undergoing Induction Chemotherapy Within the GMALL-Elderly Protocol Terminated NCT00386997 Phase 4 liposomal amphotericin B (AmBisome®)
44 Atomoxetine for Children With Acquired Attentional Disorders Following Completion of Chemotherapy for Acute Lymphocytic Leukemia Terminated NCT00299234 Phase 4 Atomoxetine
45 Randomized Controlled Trial to Test Efficacy of High-Dose Methotrexate Consolidation Therapy for BCR-ABL-Negative Acute Lymphoblastic Leukemia in Adults Unknown status NCT00131027 Phase 3 Cyclophosphamide;Daunorubicin;Vincristine;Prednisolone;L-asparaginase;Cytarabine;Etoposide;Dexamethasone;Methotrexate;Mercaptopurine;Doxorubicin;Methotrexate
46 A Phase III Randomized Trial of G-CSF Stimulated Bone Marrow vs. Conventional Bone Marrow as a Stem Cell Source In Matched Sibling Donor Transplantation Unknown status NCT00450450 Phase 3
47 Standard Risk B-precursor Acute Lymphoblastic Leukemia (ALL) Unknown status NCT00103285 Phase 3 doxorubicin hydrochloride;cytarabine;dexamethasone;pegaspargase;methotrexate;leucovorin calcium;mercaptopurine;cyclophosphamide;thioguanine;vincristine sulfate
48 An Open-Label, One-Arm, Multi-Site Trial of Precision Diagnosis Directing Histone Deacetylase Inhibitor Chidamide Target Total Therapy for Adult Early T-cell Progenitor Acute Lymphoblastic Leukemia/Lymphoma Unknown status NCT03553238 Phase 2, Phase 3 Chidamide;Dexamethasone;vincristine;Cyclophosphamide;Idarubicin;Pegaspargase;Adriamycin;Methotrexate;6-Mercaptopurine;Etoposide;Cytarabine
49 Allogeneic Stem Cell Transplantation in Children and Adolescents With Acute Lymphoblastic Leukaemia Unknown status NCT01423747 Phase 3 VP16;VP16, ATG;Fludarabine, OKT3, Treosulfan, Thiotepa;VP16, ATG
50 Allogeneic Stem Cell Transplantation in Children and Adolescents With Acute Lymphoblastic Leukaemia Unknown status NCT01423500 Phase 3 VP16;VP16, ATG;Fludarabine, OKT3, Treosulfan, Thiotepa;VP16, ATG

Search NIH Clinical Center for Leukemia, Acute Lymphoblastic

Inferred drug relations via UMLS 71 / NDF-RT 51 :


ASPARAGINASE
Cyclophosphamide
Idarubicin
Idarubicin Hydrochloride
Ifosfamide
mercaptopurine
pegaspargase
sargramostim

Cell-based therapeutics:


LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database
Read about Leukemia, Acute Lymphoblastic cell therapies at LifeMap Discovery.
Stem-cell-based therapeutic approaches for Leukemia, Acute Lymphoblastic:
Hemacord, umbilical cord blood-derived hematopoietic progenitor cells for hematopoietic reconstitution
Hematopoietic stem cells for treatment of hematologic malignancies
NiCord, umbilical cord blood-derived stem/progenitor cells for hemotological diseases
Umbilical cord-derived hematopoietic stem cells for treatment of acute lymphoblastic leukemia
Embryonic/Adult Cultured Cells Related to Leukemia, Acute Lymphoblastic:
Umbilical cord blood-derived hematopoietic progenitor cells (HEMACORD) PMIDs: 9828244
Bone marrow-derived hematopoietic stem cells
Umbilical cord blood-derived stem cells (NiCord) PMIDs: 22198152
Umbilical cord blood-derived hematopoietic stem cells (family) PMIDs: 17968329

Cochrane evidence based reviews: precursor cell lymphoblastic leukemia-lymphoma

Sources

Genetic Tests for Leukemia, Acute Lymphoblastic

About this section

Genetic tests related to Leukemia, Acute Lymphoblastic:

# Genetic test Affiliating Genes
1 Leukemia, Acute Lymphoblastic, Susceptibility to 29
2 B-Cell Acute Lymphoblastic Leukemia 29
Sources

Anatomical Context for Leukemia, Acute Lymphoblastic

About this section

MalaCards organs/tissues related to Leukemia, Acute Lymphoblastic:

40
Bone, Bone Marrow, T Cells, Myeloid, Brain, Liver, Spleen
LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database

Cells/anatomical compartments in embryo or adult related to Leukemia, Acute Lymphoblastic:
# Tissue Anatomical CompartmentCell Relevance
1 Blood Hematopoietic Bone Marrow Hematopoietic Stem Cells Potential therapeutic candidate
2 Blood Peripheral Blood Mature B-Cells Affected by disease
3 Blood Hematopoietic Bone Marrow Small Pre B-Cells Affected by disease
Sources

Publications for Leukemia, Acute Lymphoblastic

About this section

Articles related to Leukemia, Acute Lymphoblastic:

(show top 50) (show all 26883)
# Title Authors PMID Year
1
FLT3 mutations in childhood acute lymphoblastic leukemia. 57 61 6
14670924 2004
2
First case of aplastic anemia in a Japanese child with a homozygous missense mutation in the NBS1 gene (I171V) associated with genomic instability. 54 6 61
15338273 2004
3
PAX5-driven subtypes of B-progenitor acute lymphoblastic leukemia. 61 6
30643249 2019
4
RAG-mediated recombination is the predominant driver of oncogenic rearrangement in ETV6-RUNX1 acute lymphoblastic leukemia. 61 57
24413735 2014
5
Global chromatin profiling reveals NSD2 mutations in pediatric acute lymphoblastic leukemia. 61 57
24076604 2013
6
A recurrent germline PAX5 mutation confers susceptibility to pre-B cell acute lymphoblastic leukemia. 61 6
24013638 2013
7
Exome sequencing identifies mutation in CNOT3 and ribosomal genes RPL5 and RPL10 in T-cell acute lymphoblastic leukemia. 61 57
23263491 2013
8
Genetic inactivation of the polycomb repressive complex 2 in T cell acute lymphoblastic leukemia. 61 57
22237151 2012
9
Oncogenic IL7R gain-of-function mutations in childhood T-cell acute lymphoblastic leukemia. 61 57
21892159 2011
10
PHF6 mutations in T-cell acute lymphoblastic leukemia. 61 57
20228800 2010
11
Verification of the susceptibility loci on 7p12.2, 10q21.2, and 14q11.2 in precursor B-cell acute lymphoblastic leukemia of childhood. 61 57
20042726 2010
12
Rearrangement of CRLF2 in B-progenitor- and Down syndrome-associated acute lymphoblastic leukemia. 61 57
19838194 2009
13
Germline genomic variants associated with childhood acute lymphoblastic leukemia. 61 57
19684603 2009
14
Loci on 7p12.2, 10q21.2 and 14q11.2 are associated with risk of childhood acute lymphoblastic leukemia. 61 57
19684604 2009
15
Fusion of NUP214 to ABL1 on amplified episomes in T-cell acute lymphoblastic leukemia. 61 57
15361874 2004
16
Mutations in the Nijmegen Breakage Syndrome gene (NBS1) in childhood acute lymphoblastic leukemia (ALL). 61 6
11325820 2001
17
Hematopoietic malignancies demonstrate loss-of-function mutations of BAX. 61 57
9531611 1998
18
Leukaemia hijacks a neural mechanism to invade the central nervous system. 57
30022166 2018
19
Histidine catabolism is a major determinant of methotrexate sensitivity. 57
29995852 2018
20
Clonal evolution mechanisms in NT5C2 mutant-relapsed acute lymphoblastic leukaemia. 57
29342136 2018
21
Metabolic gatekeeper function of B-lymphoid transcription factors. 57
28192788 2017
22
Germline De Novo Mutations in GNB1 Cause Severe Neurodevelopmental Disability, Hypotonia, and Seizures. 6
27108799 2016
23
Mutations in G protein β subunits promote transformation and kinase inhibitor resistance. 6
25485910 2015
24
Contrasting roles of histone 3 lysine 27 demethylases in acute lymphoblastic leukaemia. 57
25132549 2014
25
Loss of oncogenic Notch1 with resistance to a PI3K inhibitor in T-cell leukaemia. 57
25043004 2014
26
The genetic basis of early T-cell precursor acute lymphoblastic leukaemia. 57
22237106 2012
27
BCL6 enables Ph+ acute lymphoblastic leukaemia cells to survive BCR-ABL1 kinase inhibition. 57
21593872 2011
28
CREBBP mutations in relapsed acute lymphoblastic leukaemia. 57
21390130 2011
29
Hypermethylation of specific microRNA genes in MLL-rearranged infant acute lymphoblastic leukemia: major matters at a micro scale. 61 47
21116279 2011
30
Genetic variegation of clonal architecture and propagating cells in leukaemia. 57
21160474 2011
31
Identification of new microRNA genes and aberrant microRNA profiles in childhood acute lymphoblastic leukemia. 47 61
18923441 2009
32
MicroRNA expression signatures accurately discriminate acute lymphoblastic leukemia from acute myeloid leukemia. 47 61
18056805 2007
33
Genome-wide analysis of genetic alterations in acute lymphoblastic leukaemia. 57
17344859 2007
34
Identification of novel FLT-3 Asp835 mutations in adult acute myeloid leukaemia. 6
11442493 2001
35
Activating mutation of D835 within the activation loop of FLT3 in human hematologic malignancies. 6
11290608 2001
36
Sequence and analysis of the human ABL gene, the BCR gene, and regions involved in the Philadelphia chromosomal translocation. 57
7665185 1995
37
A new fused transcript in Philadelphia chromosome positive acute lymphocytic leukaemia. 57
2825022 1987
38
A novel c-abl protein product in Philadelphia-positive acute lymphoblastic leukaemia. 57
3543692 1987
39
Unique forms of the abl tyrosine kinase distinguish Ph1-positive CML from Ph1-positive ALL. 57
3541203 1987
40
A longitudinal analysis of chromosomal abnormalities in disease progression from MGUS/SMM to newly diagnosed and relapsed multiple myeloma. 42
33392702 2021
41
HTLV-1 Replication and Adult T Cell Leukemia Development. 42
33200368 2021
42
Increased incidence of adult T cell leukemia-lymphoma and peripheral T cell lymphoma-not otherwise specified with limited improvement in overall survival: a retrospective analysis using data from the population-based Osaka Cancer Registry. 42
33089366 2021
43
Polymorphisms of the gamma-glutamyl hydrolase gene and risk of relapse to acute lymphoblastic leukemia in Mexico. 54 61
20197200 2010
44
Association between the methylenetetrahydrofolate reductase polymorphisms and risk of acute lymphoblastic leukemia in Serbian children. 61 54
20445408 2010
45
Glucocorticoid receptor knock down reveals a similar apoptotic threshold but differing gene regulation patterns in T-cell and pre-B-cell acute lymphoblastic leukemia. 61 54
20170710 2010
46
IL-7 receptor is expressed on adult pre-B-cell acute lymphoblastic leukemia and other B-cell derived neoplasms and correlates with expression of proliferation and survival markers. 54 61
20060740 2010
47
Reversible posterior leukoencephalopathy syndrome in childhood: report of nine cases and review of the literature. 54 61
19809787 2010
48
Identification of Zfp521/ZNF521 as a cooperative gene for E2A-HLF to develop acute B-lineage leukemia. 61 54
20062079 2010
49
Simultaneous detection of MDR1 and WT1 gene expression to predict the prognosis of adult acute lymphoblastic leukemia. 61 54
20423567 2010
50
STAT5 in B cell development and leukemia. 61 54
20227268 2010
Sources

Variations for Leukemia, Acute Lymphoblastic

About this section

ClinVar genetic disease variations for Leukemia, Acute Lymphoblastic:

6 (show top 50) (show all 58)
# Gene Name Type Significance ClinVarId dbSNP ID GRCh37 Pos GRCh38 Pos
1 IKZF1 NM_006060.6(IKZF1):c.851-1312A>G SNV association 691984 rs11978267 7:50466304-50466304 7:50398606-50398606
2 IKZF1 NM_006060.6(IKZF1):c.*2279T>G SNV association 694328 rs4132601 7:50470604-50470604 7:50402906-50402906
3 PAX5 P80R Variation Pathogenic 624590
4 NBN NM_002485.4(NBN):c.1903A>T (p.Lys635Ter) SNV Pathogenic 142559 rs587782545 8:90960063-90960063 8:89947835-89947835
5 NBN NM_002485.4(NBN):c.1030C>T (p.Gln344Ter) SNV Pathogenic 190229 rs767215758 8:90971047-90971047 8:89958819-89958819
6 GNB1 NM_002074.5(GNB1):c.239T>A (p.Ile80Asn) SNV Pathogenic 224715 rs752746786 1:1737942-1737942 1:1806503-1806503
7 FLT3 NM_004119.3(FLT3):c.2504A>T (p.Asp835Val) SNV Pathogenic 16272 rs121909646 13:28592641-28592641 13:28018504-28018504
8 FLT3 NM_004119.3(FLT3):c.2503G>T (p.Asp835Tyr) SNV Pathogenic 16276 rs121913488 13:28592642-28592642 13:28018505-28018505
9 FLT3 NM_004119.3(FLT3):c.1777_1779del (p.Asp593del) Deletion Pathogenic 16278 rs587776834 13:28608277-28608279 13:28034140-28034142
10 ETV6 NM_001987.4(ETV6):c.1046T>C (p.Leu349Pro) SNV Pathogenic 190241 rs786205155 12:12037415-12037415 12:11884481-11884481
11 ETV6 NM_001987.4(ETV6):c.1153-5_1153-1del Microsatellite Pathogenic 190240 12:12038855-12038859 12:11885921-11885925
12 ACTB NP_001092.1(ACTB):p.Val209Leu protein only Pathogenic 218133
13 GNB1 NM_002074.5(GNB1):c.227A>G (p.Asp76Gly) SNV Pathogenic 224711 rs869312821 1:1737954-1737954 1:1806515-1806515
14 CRLF2 NM_022148.4(CRLF2):c.695T>G (p.Phe232Cys) SNV Pathogenic 376003 rs1057519743 Y:1264966-1264966 X:1196852-1196852
15 JAK2 NM_004972.3(JAK2):c.2048G>C (p.Arg683Thr) SNV Pathogenic 375952 rs1057519722 9:5078361-5078361 9:5078361-5078361
16 JAK2 NM_004972.3(JAK2):c.2049A>C (p.Arg683Ser) SNV Pathogenic 375953 rs1057519723 9:5078362-5078362 9:5078362-5078362
17 JAK2 NM_004972.3(JAK2):c.2047A>G (p.Arg683Gly) SNV Pathogenic 375951 rs1057519721 9:5078360-5078360 9:5078360-5078360
18 JAK2 NM_004972.3(JAK2):c.2049A>T (p.Arg683Ser) SNV Pathogenic 375954 rs1057519723 9:5078362-5078362 9:5078362-5078362
19 JAK1 NM_002227.4(JAK1):c.1901C>A (p.Ala634Asp) SNV Likely pathogenic 225075 rs869312953 1:65312418-65312418 1:64846735-64846735
20 NBN NM_001024688.2(NBN):c.-141_-140del Deletion Likely pathogenic 371121 rs767454740 8:90994964-90994965 8:89982736-89982737
21 NBN NM_002485.4(NBN):c.2140C>T (p.Arg714Ter) SNV Likely pathogenic 182737 rs730881864 8:90955525-90955525 8:89943297-89943297
22 ABL1 NM_005157.6(ABL1):c.757T>C (p.Tyr253His) SNV Likely pathogenic 12627 rs121913461 9:133738357-133738357 9:130862970-130862970
23 JAK1 NM_002227.4(JAK1):c.1972G>T (p.Val658Phe) SNV Likely pathogenic 376030 rs1057519753 1:65312347-65312347 1:64846664-64846664
24 IL7R NM_002185.5(IL7R):c.553A>T (p.Ser185Cys) SNV Likely pathogenic 376098 rs1057519759 5:35873597-35873597 5:35873495-35873495
25 FGFR1 NM_015850.4(FGFR1):c.1962G>C (p.Lys654Asn) SNV Likely pathogenic 376428 rs1057519897 8:38272306-38272306 8:38414788-38414788
26 JAK3 NM_000215.3(JAK3):c.394C>A (p.Pro132Thr) SNV Likely pathogenic 134580 rs3212723 19:17954215-17954215 19:17843406-17843406
27 FGFR1 NM_023110.2(FGFR1):c.1966A>G (p.Lys656Glu) SNV Likely pathogenic 224897 rs869320694 8:38272308-38272308 8:38414790-38414790
28 JAK3 NM_000215.3(JAK3):c.2164G>A (p.Val722Ile) SNV Likely pathogenic 134573 rs3213409 19:17945696-17945696 19:17834887-17834887
29 JAK1 NM_002227.4(JAK1):c.1937C>T (p.Ser646Phe) SNV Likely pathogenic 376099 rs151047872 1:65312382-65312382 1:64846699-64846699
30 PAX5 NM_016734.3(PAX5):c.547G>A (p.Gly183Ser) SNV risk factor 88892 rs398123063 9:37002702-37002702 9:37002705-37002705
31 ABL1 NM_005157.6(ABL1):c.944C>T (p.Thr315Ile) SNV Likely pathogenic 12624 rs121913459 9:133748283-133748283 9:130872896-130872896
32 NBN NM_002485.5(NBN):c.511A>G (p.Ile171Val) SNV risk factor 6946 rs61754966 8:90990521-90990521 8:89978293-89978293
33 NBN NM_002485.4(NBN):c.260T>C (p.Phe87Ser) SNV Uncertain significance 187236 rs786203573 8:90993663-90993663 8:89981435-89981435
34 HOXD4 NM_014621.3(HOXD4):c.242A>T (p.Glu81Val) SNV Uncertain significance 14888 rs104893636 2:177016603-177016603 2:176151875-176151875
35 NBN NM_002485.4(NBN):c.390A>G (p.Gln130=) SNV Uncertain significance 625984 rs146150499 8:90993052-90993052 8:89980824-89980824
36 NBN NM_002485.5(NBN):c.511A>G (p.Ile171Val) SNV Uncertain significance 6946 rs61754966 8:90990521-90990521 8:89978293-89978293
37 NBN NM_002485.4(NBN):c.456G>A (p.Met152Ile) SNV Uncertain significance 127872 rs201816949 8:90992986-90992986 8:89980758-89980758
38 NBN NM_002485.4(NBN):c.683T>G (p.Ile228Arg) SNV Uncertain significance 186350 rs777460725 8:90983420-90983420 8:89971192-89971192
39 NBN NM_002485.4(NBN):c.505C>T (p.Arg169Cys) SNV Uncertain significance 127873 rs182756889 8:90990527-90990527 8:89978299-89978299
40 NBN NM_002485.5(NBN):c.119C>T (p.Ser40Leu) SNV Uncertain significance 141146 rs587781530 8:90995002-90995002 8:89982774-89982774
41 NBN NM_002485.4(NBN):c.2149A>T (p.Thr717Ser) SNV Uncertain significance 127865 rs587780093 8:90955516-90955516 8:89943288-89943288
42 NBN NM_002485.4(NBN):c.595C>T (p.Pro199Ser) SNV Uncertain significance 127874 rs587780097 8:90983508-90983508 8:89971280-89971280
43 NBN NM_002485.5(NBN):c.1262T>C (p.Leu421Ser) SNV Uncertain significance 127009 rs104895032 8:90967646-90967646 8:89955418-89955418
44 NBN NM_002485.5(NBN):c.425A>G (p.Asn142Ser) SNV Uncertain significance 127871 rs769414 8:90993017-90993017 8:89980789-89980789
45 NBN NM_002485.5(NBN):c.628G>T (p.Val210Phe) SNV Uncertain significance 127014 rs61754796 8:90983475-90983475 8:89971247-89971247
46 NBN NM_002485.4(NBN):c.1999T>C (p.Ser667Pro) SNV Uncertain significance 127863 rs587780091 8:90958439-90958439 8:89946211-89946211
47 PAX5 NM_016734.3(PAX5):c.1013-1G>A SNV Uncertain significance 517139 rs1554646594 9:36846927-36846927 9:36846930-36846930
48 PAX5 NM_016734.3(PAX5):c.435G>C (p.Gln145His) SNV Uncertain significance 587563 rs758368747 9:37006510-37006510 9:37006513-37006513
49 NBN NM_002485.5(NBN):c.2215C>G (p.Leu739Val) SNV Uncertain significance 182730 rs370058152 8:90949273-90949273 8:89937045-89937045
50 NBN NM_002485.4(NBN):c.1034G>T (p.Gly345Val) SNV Uncertain significance 127852 rs587780089 8:90971043-90971043 8:89958815-89958815

UniProtKB/Swiss-Prot genetic disease variations for Leukemia, Acute Lymphoblastic:

73
# Symbol AA change Variation ID SNP ID
1 PAX5 p.Gly183Ser VAR_070682 rs398123063

Copy number variations for Leukemia, Acute Lymphoblastic from CNVD:

7 (show top 50) (show all 2943)
# CNVD ID Chromosome Start End Type Gene Symbol CNVD Disease
1 13316 1 1 117600000 Loss Acute lymphoblastic leukemia
2 13371 17 1 22200000 Deletion TP53 Acute lymphoblastic leukemia
3 13410 1 1 2300000 Copy number Acute lymphoblastic leukemia
4 13773 1 1 35400000 Duplication Acute lymphoblastic leukemia
5 13788 1 1 40300000 Duplication Acute lymphoblastic leukemia
6 13790 1 1 46500000 Gain Acute lymphoblastic leukemia
7 13836 12 10000000 12600000 Deletion ETV6 Acute lymphoblastic leukemia
8 13906 1 100818677 103024856 Loss DPH5 Acute lymphoblastic leukemia
9 13907 1 100818677 103024856 Loss EXTL2 Acute lymphoblastic leukemia
10 13908 1 100818677 103024856 Loss OLFM3 Acute lymphoblastic leukemia
11 13909 1 100818677 103024856 Loss S1PR1 Acute lymphoblastic leukemia
12 13910 1 100818677 103024856 Loss SLC30A7 Acute lymphoblastic leukemia
13 13911 1 100818677 103024856 Loss VCAM1 Acute lymphoblastic leukemia
14 13991 1 102370195 102561809 Deletion Acute lymphoblastic leukemia
15 14292 1 106673274 107678605 Loss NTNG1 Acute lymphoblastic leukemia
16 14293 1 106673274 107678605 Loss PRMT6 Acute lymphoblastic leukemia
17 14369 1 107716342 144004701 Loss ADAM30 Acute lymphoblastic leukemia
18 14370 1 107716342 144004701 Loss ADORA3 Acute lymphoblastic leukemia
19 14371 1 107716342 144004701 Loss AKR7A2P1 Acute lymphoblastic leukemia
20 14372 1 107716342 144004701 Loss AHCYL1 Acute lymphoblastic leukemia
21 14373 1 107716342 144004701 Loss AKNAD1 Acute lymphoblastic leukemia
22 14374 1 107716342 144004701 Loss ALX3 Acute lymphoblastic leukemia
23 14375 1 107716342 144004701 Loss AMIGO1 Acute lymphoblastic leukemia
24 14376 1 107716342 144004701 Loss AMPD1 Acute lymphoblastic leukemia
25 14377 1 107716342 144004701 Loss AMPD2 Acute lymphoblastic leukemia
26 14378 1 107716342 144004701 Loss AP4B1 Acute lymphoblastic leukemia
27 14379 1 107716342 144004701 Loss ATP1A1 Acute lymphoblastic leukemia
28 14380 1 107716342 144004701 Loss ATP5PB Acute lymphoblastic leukemia
29 14381 1 107716342 144004701 Loss ATXN7L2 Acute lymphoblastic leukemia
30 14382 1 107716342 144004701 Loss BCAS2 Acute lymphoblastic leukemia
31 14383 1 107716342 144004701 Loss BCL2L15 Acute lymphoblastic leukemia
32 14384 1 107716342 144004701 Loss LRIF1 Acute lymphoblastic leukemia
33 14385 1 107716342 144004701 Loss PFN1P2 Acute lymphoblastic leukemia
34 14386 1 107716342 144004701 Loss MAB21L3 Acute lymphoblastic leukemia
35 14387 1 107716342 144004701 Loss C1orf162 Acute lymphoblastic leukemia
36 14388 1 107716342 144004701 Loss INKA2 Acute lymphoblastic leukemia
37 15383 1 115048600 115061038 Copy number NRAS Acute lymphoblastic leukemia
38 15429 1 115400000 222100000 Gain Acute lymphoblastic leukemia
39 15832 1 119869201 120436800 Loss HMGCS2 Acute lymphoblastic leukemia
40 15833 1 119869201 120436800 Loss NBPF7 Acute lymphoblastic leukemia
41 15834 1 119869201 120436800 Loss NOTCH2 Acute lymphoblastic leukemia
42 15835 1 119869201 120436800 Loss PHGDH Acute lymphoblastic leukemia
43 15836 1 119869201 120436800 Loss REG4 Acute lymphoblastic leukemia
44 15837 1 119869201 120436800 Loss ZNF697 Acute lymphoblastic leukemia
45 15979 1 120700000 169100000 Loss CREG1 Acute lymphoblastic leukemia
46 16426 1 124300000 247249719 Deletion Acute lymphoblastic leukemia
47 16427 1 124300000 247249719 Duplication Acute lymphoblastic leukemia
48 16474 1 125000000 249250621 Copy number Acute lymphoblastic leukemia
49 16502 1 12600000 16100000 Deletion Acute lymphoblastic leukemia
50 16592 1 128000000 185104377 Copy number Acute lymphoblastic leukemia
Sources

Expression for Leukemia, Acute Lymphoblastic

About this section
Search GEO for disease gene expression data for Leukemia, Acute Lymphoblastic.
Sources

Pathways for Leukemia, Acute Lymphoblastic

About this section

Pathways related to Leukemia, Acute Lymphoblastic according to KEGG:

36
# Name Kegg Source Accession
1 Transcriptional misregulation in cancer hsa05202

Pathways related to Leukemia, Acute Lymphoblastic according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1
MicroRNAs in cancer 36
11.42 MIR335 MIR203A MIR155 MIR152
2
Hematopoietic Stem Cell Gene Regulation by GABP alpha/beta Complex 1
10.3 FLT3 ETV6
Sources

GO Terms for Leukemia, Acute Lymphoblastic

About this section

Biological processes related to Leukemia, Acute Lymphoblastic according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 gene silencing by miRNA GO:0035195 9.35 MIR335 MIR203A MIR196B MIR155 MIR152
2 dendritic cell differentiation GO:0097028 9.16 MIR155 FLT3
3 negative regulation of cytokine production involved in inflammatory response GO:1900016 8.8 MIR203A MIR155 MIR152
Sources

Sources for Leukemia, Acute Lymphoblastic

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 05-Mar-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....